Anhydroerythromycin A

Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively) . Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.

Product Specifications

CAS Number

[23893-13-2]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Antibiotic; Bacterial

Type

Natural Products

Related Pathways

Anti-infection

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/anhydroerythromycin-a.html

Solubility

10 mM in DMSO

Smiles

C[C@H]([C@H]1O)[C@@](O[C@@]1([C@H](OC2=O)CC)C)([C@@H](C3)C)O[C@]3([C@@H]([C@H]([C@@H]([C@H]2C)O[C@H](O[C@H]4C)C[C@](C)([C@H]4O)OC)C)O[C@H](O[C@@H]5C)[C@@H]([C@H](C5)N(C)C)O)C

Molecular Formula

C37H65NO12

Molecular Weight

715.91

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Sunazuka T, et al. Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. J Antibiot (Tokyo) . 1999 Jan;52 (1) :71-4.